Cornell University
INSULIN-SENSITIZING ACTION OF FIBROBLAST GROWTH FACTOR 21 IN RUMINANTS
Abstract
dc:description.abstractInsulin resistance is a fundamental mechanism that regulates nutrient partitioning during pregnancy and lactation. However, excessive insulin resistance can lead to metabolic disorders, such as pregnancy toxemia in late-pregnant polytocous ewes and ketosis and fatty liver in early-lactating high-yielding dairy cows, compromising maternal health, fetal development, and milk production. While fibroblast growth factor 21 (FGF21) has been identified as a potent insulin-sensitizing hormone in rodents and non-human primates, its effects in ruminants are not well understood. Therefore, this dissertation aims to investigate the insulin-sensitizing action of exogenous FGF21 in ruminants experiencing energy insufficiency or insulin resistance. In Chapter 3, an experiment was conducted involving non-pregnant and non-lactating sheep that were fed either at 2-fold or 0.5-fold of their estimated maintenance energy requirement to test whether negative energy balance limits the insulin-sensitizing action of FGF21. Each group underwent two experimental periods during which they received daily injections of either excipient or FGF21 for 12 days. The results showed a significant improvement in insulin action in well-fed sheep, while underfed sheep exhibited a less pronounced response under basal conditions. However, the insulin-sensitizing effect of FGF21 in underfed sheep became apparent during metabolic tolerance tests, as evidenced by reduced insulin secretion during the glucose tolerance test (GTT) and increased glucose disposal during the insulin tolerance test (ITT). In Chapter 4, experiments were conducted to evaluate the potential of exogenous FGF21 to enhance insulin action in two proven models of insulin resistance in ruminants. The first experiment involved obese and lean sheep to determine whether FGF21 could mitigate obesity-induced insulin resistance. Each group underwent two experimental periods during which they received daily injections of either excipient or FGF21 for 7 days. The results showed that FGF21 therapy reduced plasma glucose and insulin levels in obese sheep over the 7-day treatment period. This improvement in insulin action in FGF21-treated obese sheep was further supported by observations of reduced insulin secretion during the GTT and increased glucose disposal during the ITT. In the second experiment, sheep were given either daily injections of excipient or a single injection of prolonged-release growth hormone (GH) on day 1, followed by daily injections of excipient or FGF21 for 7 days to test whether exogenous FGF21 could counter GH-driven insulin resistance. GH-treated sheep experienced plasma glucose and insulin levels that were 2.5- and 9.4-fold those of control sheep. FGF21 co-administration was able to rescue the hyperglycemia and hyperinsulinemia of GH-treated sheep. These findings demonstrate that FGF21 can effectively mitigate not only obesity-induced insulin resistance but also extreme insulin resistance induced by GH excess.
Degree
thesis:*- Name thesis:degree_name
- Ph. D., Animal Science
- Level thesis:degree_level
- Doctor of Philosophy
- Discipline thesis:degree_discipline
- Animal Science
- Grantor
- Cornell University
- Year dc:date.issued
- 2024
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Ramos dos Santos, Antonio Carlos
- Chair dc:contributor.chair
-
- Boisclair, Yves
- Committee members dc:contributor.committeemember
-
- Mann, Sabine
- Quirk, Susan
- Van Amburgh, Michael
Subjects
dc:subject × 6Rights
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Dc Identifier Bibid
- 16611886
- Dc Identifier Other
-
ProQuest Submission ID: 14403
ProQuest Publication ID: 31334965